Smith & Nephew SNATS Debt/Equity Ratio 2010-2024 | SNN

Smith & Nephew SNATS debt/equity ratio for the quarter ending June 30, 2024 was 0.63.

  • Smith & Nephew SNATS average debt/equity ratio for 2023 was 0.47, a 0% increase from 2022.
  • Smith & Nephew SNATS average debt/equity ratio for 2022 was 0.47, a 11.32% decline from 2021.
  • Smith & Nephew SNATS average debt/equity ratio for 2021 was 0.53, a 7.02% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Smith & Nephew SNATS Debt/Equity Ratio 2010-2024 | SNN

  • Smith & Nephew SNATS average debt/equity ratio for 2023 was 0.47, a 0% increase from 2022.
  • Smith & Nephew SNATS average debt/equity ratio for 2022 was 0.47, a 11.32% decline from 2021.
  • Smith & Nephew SNATS average debt/equity ratio for 2021 was 0.53, a 7.02% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$203.2B
Stryker (SYK)$148.2B
Boston Scientific (BSX)$133.1B
EssilorLuxottica (ESLOY)$113.5B
Medtronic (MDT)$109B
Haleon (HLN)$42.9B
Lonza Group Ag (LZAGY)$42.1B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35B
Terumo (TRUMY)$29.2B
Koninklijke Philips (PHG)$24.4B
Zimmer Biomet Holdings (ZBH)$22.1B
Insulet (PODD)$18.4B
Baxter (BAX)$16.6B
BellRing Brands (BRBR)$9.5B
Bio-Rad Laboratories (BIO)$9B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$5.5B
TG Therapeutics (TGTX)$4.7B
Haemonetics (HAE)$4.3B
ICU Medical (ICUI)$4.2B
Prestige Consumer Healthcare (PBH)$4.1B
Perrigo (PRGO)$3.7B
Envista Holdings (NVST)$3.5B
Neogen (NEOG)$3.3B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.6B
Warby Parker (WRBY)$2.3B